But the outpouring of internal documents shows, once again, that this type of high-stakes, multinational litigation is always much more than a simple courtroom battle.
By stringing together thousands of these so-called droplets (which measure about 50 microns across) using a custom-built 3D printer, the Oxford team believes it has engineered a "new type of material" that could eventually be used to ferry drugs throughout our internal systems to a specific target site, fill-in for damaged tissues or even mimic neural pathways via specially printed protein pores.
This internal struggle with choosing (and therefore rejecting), I think, is what makes determining which type of business to start so challenging for entrepreneurs.